We recently showed that GARP-expressing Tregs were required for the anti-tumor activity of antibodies that block production of active TGF-β1 from GARP:TGF-β1 complexes on the surface of Tregs in mice transplanted with syngeneic colon carcinoma cells [67]. The gene discussed is LRRC32; the disease is neoplasm.